Oncolytics Biotech Inc. has announced updated results from the squamous cell anal carcinoma (SCAC) cohort of the GOBLET study, evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later (≥2L) metastatic SCAC. The combination achieved an objective response rate $(ORR)$ of 30% among 20 evaluable patients, which is more than double the 13.8% historical benchmark for the only FDA-approved immunotherapy in this setting. The median duration of response was 15.5 months, compared to 9.5 months for the current standard of care. These results have already been presented, and additional efficacy data are expected to be reported as patient follow-up continues. Oncolytics plans to discuss a potential single-arm accelerated approval study with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026, with a potential study launch date in the first half of 2026.